当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
22期
136-137
,共2页
惠迪%肠易激综合征%腹痛%腹胀%大便异常
惠迪%腸易激綜閤徵%腹痛%腹脹%大便異常
혜적%장역격종합정%복통%복창%대편이상
Huidi mesalazine%Irritable bowel syndrome (IBS)%Bellyache%Abdominal discomfort%Abnormal stool
目的探讨美沙拉嗪肠溶片(惠迪)治疗肠易激综合征(IBS)患者的临床疗效。方法选取2010年2月-2012年6月至上海市第八人民医院就诊的52例不同亚型的IBS患者进行自身对照试验,均予惠迪口服,500 mg,4次/d,治疗1个月(30 d)。监测治疗前后的腹痛强度、腹胀、大便情况。结果(1)所有亚型的IBS患者在治疗后疼痛得分均降低[腹泻型由(7.3±0.4)降至(2.2±0.8),便秘型由(6.4±0.7)降至(1.1±0.2),混合型由(8.1±0.6)降至(2.7±0.5),不定型由(8.9±0.5)降至(3.6±0.8)],疼痛强度明显降低。(2)大便的各种异常症状发病率均明显降低,(腹泻型由100.0%降至6.3%,便秘型由100.0%降至38.1%,混合型由100%降至20.0%,不定型由100.0%降至40.0%)。(3)腹部不适的症状也得到减轻。发病率明显降低(腹泻型由68.8%降至18.8%,便秘型由95.2%降至19.0%,混合型由90.0%降至30.0%,不定型由80.0%降至40.0%)。结论惠迪能有效缓解IBS患者的多种症状,明显的减低患者的疼痛强度,显著改善腹部不适和大便异常。
目的探討美沙拉嗪腸溶片(惠迪)治療腸易激綜閤徵(IBS)患者的臨床療效。方法選取2010年2月-2012年6月至上海市第八人民醫院就診的52例不同亞型的IBS患者進行自身對照試驗,均予惠迪口服,500 mg,4次/d,治療1箇月(30 d)。鑑測治療前後的腹痛彊度、腹脹、大便情況。結果(1)所有亞型的IBS患者在治療後疼痛得分均降低[腹瀉型由(7.3±0.4)降至(2.2±0.8),便祕型由(6.4±0.7)降至(1.1±0.2),混閤型由(8.1±0.6)降至(2.7±0.5),不定型由(8.9±0.5)降至(3.6±0.8)],疼痛彊度明顯降低。(2)大便的各種異常癥狀髮病率均明顯降低,(腹瀉型由100.0%降至6.3%,便祕型由100.0%降至38.1%,混閤型由100%降至20.0%,不定型由100.0%降至40.0%)。(3)腹部不適的癥狀也得到減輕。髮病率明顯降低(腹瀉型由68.8%降至18.8%,便祕型由95.2%降至19.0%,混閤型由90.0%降至30.0%,不定型由80.0%降至40.0%)。結論惠迪能有效緩解IBS患者的多種癥狀,明顯的減低患者的疼痛彊度,顯著改善腹部不適和大便異常。
목적탐토미사랍진장용편(혜적)치료장역격종합정(IBS)환자적림상료효。방법선취2010년2월-2012년6월지상해시제팔인민의원취진적52례불동아형적IBS환자진행자신대조시험,균여혜적구복,500 mg,4차/d,치료1개월(30 d)。감측치료전후적복통강도、복창、대편정황。결과(1)소유아형적IBS환자재치료후동통득분균강저[복사형유(7.3±0.4)강지(2.2±0.8),편비형유(6.4±0.7)강지(1.1±0.2),혼합형유(8.1±0.6)강지(2.7±0.5),불정형유(8.9±0.5)강지(3.6±0.8)],동통강도명현강저。(2)대편적각충이상증상발병솔균명현강저,(복사형유100.0%강지6.3%,편비형유100.0%강지38.1%,혼합형유100%강지20.0%,불정형유100.0%강지40.0%)。(3)복부불괄적증상야득도감경。발병솔명현강저(복사형유68.8%강지18.8%,편비형유95.2%강지19.0%,혼합형유90.0%강지30.0%,불정형유80.0%강지40.0%)。결론혜적능유효완해IBS환자적다충증상,명현적감저환자적동통강도,현저개선복부불괄화대편이상。
Objective To study the clinical effects of Huidi mesalazine in patients with irritable bowel syndrome(IBS). Methods The intensity of bellyache, abdominal distension and stool are monitored after the patients treated to Huidi mesalazine, compared with the self-concentration untreated. There are 52 patients in this experiment, containing all types of IBS.Results (1)Bellyache in all patients was relieved,and the score were decreased in all types[type diarrhea from (7.3 ± 0.4) to (2.2 ± 0.8), type constipation (6.4 ± 0.7) to (1.1 ± 0.2), type mixed from (8.1 ± 0.6) to (2.7 ± 0.5), type indeifnite from (8.9 ± 0.5) to (3.6 ± 0.8)];(2) the incidence of abnormal stool symptoms was signiifcantly reduced (type diarrhea from 100%to 6.3%, type constipation from 100%to 38.1%, type mixed from 100%to 20%, type indeifnite from 100%to 40%);(3) Abdominal discomfort in some patients was relieved. The incidence rate of abdominal discomfort was decreased signiifcantly (type diarrhea from 68.8%to 18.8%, type constipation from 95.2%to 19%, type mixed from 90%to 30%, type indeifnite from 80%to 40%). Conclusion Huidi mesalazine can relieve some symptoms containing bellyache, abdominal discomfort and abnormal stool of patients with irritable bowel syndrome.